In addition to our Center’s main longitudinal research study, the University of Michigan Memory and Aging Project (UM-MAP), we invite anyone interested in participating in aging research studies to join[…]

What is aducanumab (Aduhelm™)? Aducanumab (brand name Aduhelm™) is a drug that was recently approved by the Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease. How does[…]

June 7, 2021 On June 7th, the United States Food and Drug Administration (FDA) approved Aducanumab as a medication for Alzheimer’s disease. This is the first medication targeting Alzheimer’s disease[…]

Early Serotonin System Changes in Prodromal Dementia with Lewy Bodies:  This is an NIH-funded neuroimaging study that aims to understand whether the brain’s serotonin system is a critical modifier of[…]

We are pleased to offer a session of Mindfulness-based Dementia Care this spring. This eight week course will take place every Wednesday, May 5 to June 23, from 9:30AM –[…]

This annual report reveals the burden of Alzheimer’s disease and dementia on individuals, caregivers, government and the nation’s health care system. An accompanying special report, Race, Ethnicity and Alzheimer’s in America,[…]

Looking for information about Alzheimer’s disease and related dementias? Check out the new Alzheimers.gov website! The federal government is committed to making every day better for people with dementia, their[…]

A new study reveals how APOE4 gene may increase risk for dementia. Dr. Scott Roberts, Lead of our Outreach, Recruitment, and Engagement Core and Professor of Health Behavior & Health[…]